In particular, the release noted that a phase 3 study of the drug will evaluate its ability to prevent coronavirus infection among uninfected people who have had close contact with an infected person, such as a patient’s roommate. The Phase 3 prevention study is taking place at around 100 sites and is expected to include 2000 patients in the United States, according to Regeneron.
The drug also moved to the Phase 2/3 part of two studies that tested its ability to treat hospitalized and non-hospitalized patients with Covid-1
“We are conducting simultaneous adaptive tests to move as quickly as possible to provide a potential solution to prevent and treat COVID-19 infections, even in the midst of an ongoing global pandemic,” Dr. George D. Yancopoulos, co- founder, president and scientific director of Regeneron, said in the company’s press release.
The release also noted that the trial was conducted jointly with the National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health.
Antibodies are proteins that the body naturally produces to protect the body from a threat like Covid-19. To create what are called monoclonal antibodies for a cocktail of antibodies, scientists examine thousands of antibodies to understand which ones fight the new coronavirus more effectively.
In this case, Regeneron scientists collected two antibodies, scaled them down and turned them into a drug that he hopes can be used to treat symptoms and possibly even work as a protection for vulnerable communities such as the elderly or healthcare professionals.
Regeneron is not the first company to undergo human Covid-19 antibody therapy. Eli Lilly and AbCellera started testing their antibody treatment in humans on June 1st. There are some other companies working on further antibody therapies.